Posts by: Forest Ray PhD

Forest Ray PhD

Forest Ray received his PhD in systems biology from Columbia University, where he developed tools to match drug side effects to other diseases. He has since worked as a journalist and science writer, covering topics from rare diseases to the intersection between environmental science and social justice. He currently lives in Long Beach, California.

April 7, 2021April 7, 2021

Ionis Opening Phase 3 Trial of ION363, Antisense Therapy for FUS-ALS

News

Ionis Pharmaceuticals is opening a Phase 3 safety and efficacy trial of ION363 (jacifusen) in amyotrophic lateral sclerosis (ALS) patients with confirmed mutations in the FUS gene, a known cause of juvenile-onset ... Read more

March 30, 2021March 30, 2021

First Patients Dosed in Phase 2 Trial of RT001

News

Retrotope has dosed the first patients in its recently-initiated Phase 2 clinical trial evaluating RT001 for the treatment of amyotrophic lateral sclerosis (ALS). Enrollment is open across four European sites ... Read more

March 8, 2021March 8, 2021

PharmaTher Plans to Develop Ketamine as Potential ALS Treatment

News

Under an agreement with the University of Kansas, PharmaTher has gained exclusive worldwide rights to develop and possibly commercialize ketamine as a therapy for amyotrophic lateral sclerosis (ALS). “We are ... Read more

March 4, 2021March 4, 2021

NurOwn Showed No Benefit Over Placebo in Trial, FDA Says

News

The small difference in treatment responses among amyotrophic lateral sclerosis (ALS) patients receiving NurOwn versus a placebo in a recent clinical trial likely was due to chance, the U.S. Food ... Read more

March 3, 2021March 3, 2021

PrimeC Safe, Well-tolerated; Earns US Patent Allowance

News

PrimeC is safe and well-tolerated for the treatment of amyotrophic lateral sclerosis (ALS) and showed signs of slowing disease progression in patients, findings from a recently-completed Phase 2a study show. All ... Read more

February 22, 2021February 22, 2021

Higher Suicide Risk Found for US Veterans With ALS

News

Military veterans with amyotrophic lateral sclerosis (ALS) are nearly four times as likely to commit suicide as vets without the progressive neurological disease, according to a recent study. This finding suggests ... Read more

February 12, 2021February 12, 2021

BrainStorm, FDA Discuss Plans for Manufacturing of NurOwn

News

BrainStorm Cell Therapeutics met with U.S. Food and Drug Administration (FDA) officials regarding its plans for a semi-automatic manufacturing process for NurOwn, the company’s investigational cell-based therapy for amyotrophic lateral ... Read more

February 11, 2021February 11, 2021

ALS Groups Given $20K Grants by Cytokinetics to Support Outreach Work

News

Cytokinetics awarded two amyotrophic lateral sclerosis (ALS) patient advocacy organizations grants worth $20,000, in recognition of their efforts to support their disease communities through communications, awareness, and outreach. The grants, ... Read more

February 4, 2021February 4, 2021

European Project Using Artificial Intelligence to Improve ALS Care

News

A new project run by a consortium of European institutions aims to improve the care of people with amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) through targeted use of ... Read more

January 22, 2021January 22, 2021

ALS Augmentative Communication Program Renamed for Advocate

News

Boston Children’s Hospital (BCH) is renaming its amyotrophic lateral sclerosis (ALS) Augmentative Communication Program to the Jay S. Fishman ALS-Augmentative Communication Program at Boston Children’s, the hospital announced. Fishman was CEO of ... Read more

Pin It on Pinterest